SANA
Sana Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.85
−1.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.4M | 12.8M | — | — | — |
| Gross Profit | (2.4M) | (12.8M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 160.9M | 132.0M | 208.7M | 219.8M | 201.0M |
| SG&A Expense | 44.7M | 44.3M | 64.0M | 73.3M | 71.6M |
| General & Admin Expense | 44.7M | 44.3M | 64.0M | 73.3M | 71.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | 1.9M | — | — | — |
| Total Operating Expenses | 205.6M | 178.2M | 272.7M | 293.1M | 272.6M |
| Cost and Expenses | 208.0M | 191.0M | 272.7M | 293.1M | 272.6M |
| Operating Income (EBIT) | (208.0M) | (191.0M) | (272.7M) | (293.1M) | (272.6M) |
| Non-Operating | |||||
| Interest Income | 1.5M | 3.8M | 10.5M | 9.9M | 3.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.5M | 3.8M | 10.5M | 9.9M | 3.8M |
| Other Non-Op Income/Expense | (3.8M) | (53.2M) | 6.0M | 9.9M | 3.1M |
| Non-Operating Income (excl Interest) | 3.8M | 53.2M | (6.0M) | (9.9M) | (3.1M) |
| EBT (Pre-Tax Income) | (211.8M) | (244.2M) | (266.8M) | (283.3M) | (269.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (211.8M) | (244.2M) | (266.8M) | (283.3M) | (269.5M) |
| Earnings from Cont. Ops | (211.8M) | (244.2M) | (266.8M) | (283.3M) | (269.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (211.8M) | (244.2M) | (266.8M) | (283.3M) | (269.5M) |
| Per Share | |||||
| Basic EPS | ($0.76) | ($0.96) | ($1.16) | ($1.46) | ($1.43) |
| Diluted EPS | ($0.75) | ($0.96) | ($1.16) | ($1.46) | ($1.43) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 295.7M | 253.2M | 230.9M | 194.5M | 188.3M |
| Diluted Shares Outstanding | 295.7M | 253.2M | 230.9M | 194.5M | 188.3M |
| Profitability Metrics | |||||
| EBITDA | (201.0M) | (231.4M) | (249.4M) | (258.7M) | (253.9M) |
| D&A | 10.8M | 12.8M | 17.4M | 24.6M | 15.6M |
| EBIT | (211.8M) | (244.2M) | (266.8M) | (283.3M) | (269.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026